Actively Recruiting
Early Detection of Familial Hypercholesterolemia in Children
Led by Institut Investigacio Sanitaria Pere Virgili · Updated on 2025-04-18
400
Participants Needed
2
Research Sites
902 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Heterozigous FH is an underdiagnosed disease in the paediatric population. Its early detection, would allow us to initiate lifestyle therapeutical changes and early pharmacological therapy if necessary. This is a key fact to reduce atherosclerosis progression and cardiovascular risk in adulthood. Moreover, it will allow, detecting the first and second degree affected relatives.
CONDITIONS
Official Title
Early Detection of Familial Hypercholesterolemia in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children between 2 and 18 years of age
- LDL-C level above 135 mg/dL
- Secondary causes of hypercholesterolemia such as hypothyroidism, nephrotic syndrome, diabetes, and renal insufficiency have been ruled out
- Parent has a confirmed genetic mutation or clinical diagnosis of familial hypercholesterolemia (DLCN score ≥ 8)
You will not qualify if you...
- Children younger than 2 years or older than 18 years
- Children with high cholesterol due to secondary causes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hospital Universitari Sant Joan de Reus
Reus, Tarragona, Spain, 43440
Actively Recruiting
2
Hospital Universitari Sant Joan
Reus, Tarragona, Spain, 43440
Actively Recruiting
Research Team
N
Núria Plana, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here